Bird & Bird's award winning Life Sciences Group invites you to its annual update on Tuesday 4 October 2011.
The event will consist of three parallel sessions focussing on current key issues in the Life Sciences sector.
Session 1 - Having your say at the EMA: opportunities for challenging European Medicines Agency opinions and decisions
This talk will examine the different types of opinions and decisions taken by the European Medicines Agency and its Committees and explore the various procedures available to request re-examination (including EMA's specific re-examination procedures) or, ultimately, to litigate the final decision.
This session will be relevant to anyone interested in seeking re-examination of scientific opinion and/or the challenging of final decisions.
Sarah Faircliffe, Consultant, London
Mauro Turrini, Associate, Rome
Session 2 - An update on Supplementary Protection Certificates
Does the extended protection offered by an SPC apply to a product the subject of an MA not granted pursuant to full EU procedures, or to a product for human use already the subject of an MA for veterinary use? Does it apply to a combination product for which the "basic patent" claims only one active, or where the SPC is to one component of that combination? Can one get a zero or negative term SPC to allow a paediatric extension to be secured? The current references to the CJEU will be discussed, including the recent decisions in Synthon - Merz and Generics - Synaptech, the references in Neurim, and as to the protective scope of an SPC in Novartis - Actavis, as well as the opinions of the Advocates General in Medeva/Georgetown and Sitagliptin.
This session will be relevant to counsel or senior management with an interest in understanding the SPC system and the current controversies before the CJEU.
Trevor Cook, Partner, London
Jennifer Jones, Associate, London
Session 3 - How to realise a successful sale in an M&A transaction: war stories from the front line
With special guest speaker, Ian Crosbie, Managing Director, Healthcare Investment Banking at Jefferies, one of the largest and most experienced healthcare investment banking teams in the world.
With the challenging public markets, M&A looks to be a more practical exit strategy. This session will deal with first hand experiences, describing what can be done to secure a successful exit for growth companies in current market conditions and will be relevant to anyone responsible for corporate development, as well as in-house corporate lawyers and C-level executives at start up companies who may be looking for guidance both legal and from an investment side.
Richard Eaton, Partner, London
Ian Crosbie, Managing Director, Healthcare Investment Banking, Jefferies
We hope you can join us.
Registration and refreshments
Networking drinks and canapés
For further information, or to register to attend this seminar please contact the Events Team at firstname.lastname@example.org or call +44 (0)20 7415 6000.